Clinical trials: Atrophy of Vagina
Atrophy of Vagina, Vaginal Ulceration
Vaginal Creams to Reduce Vaginal Erosion in Pessary Users
To compare the use of Estrace ® vaginal cream against a placebo vaginal cream in reducing symptomatic vaginal discharge and vaginal erosion in patients who are using the Gellhorn or Ring with support pessaries.
- Conditions
- Atrophy of Vagina, Vaginal Ulceration, Vaginitis
- Trial name
- NCT02316249
- Testing
- Estradiol
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Northwell Health
Breast Cancer
Evaluation of Innovative Therapeutic Approaches of Vaginal and Sexual Dysfunction After Breast Cancer Treatment
Many studies have shown that locoregional treatment (surgery, radiotherapy) and systemic treatment (endocrine therapy and chemotherapy) for breast cancer (BC) may impact sexuality by causing physical and/or psychological damages.
- Trial name
- EPIONE-01 (NCT04713917)
- Testing
- Hyaluronique Acid Gel, Laser CO2, Hyaluronique Acid Injection
- Where
- France
- Volunteers
- 330 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Vaginismus, Vaginal Atrophy
Hydration and Acceptability of the Genital and Skin Mucosa of a Vaginal Moisturizer in Menopausal Women
Hyaluronic Acid is indicated for the relief of vaginal dryness, itching, and irritation, or the reduction of vaginal lubrication with prolonged hydration effects for up to 72 hours.
- Conditions
- Vaginismus, Vaginal Atrophy, Menopause
- Trial name
- NCT06564883
- Testing
- 0.20% sodium hyaluronate gel
- Volunteers
- 45 people
- Sponsor
- Biolab Sanus Farmaceutica
Vaginal Atrophy
Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.005%, 0.002%, 0.0008% Estriol Vaginal Gel) for the Treatment of Vaginal Dryness in Postmenopausal Women With Vulvovaginal Atrophy
A Phase 2, Dose-ranging, 12-week Randomized, Double-blind, Placebo controlled, Parallel-group Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.005% Estriol Vaginal Gel…
- Trial name
- NCT02967510
- Testing
- Estriol
- Where
- 23 sites in Czechia, Hungary and 3 more
- Volunteers
- 283 people
- Sponsor
- ITF Research Pharma, S.L.U.
Vaginal Atrophy
Clinical Study of the CO2RE Laser Device Performance for Vaginal Atrophy Treatments
The CO2RE laser system is a fractional CO2 laser that is FDA approved under a 510(k) K101321 for dermatologic procedures requiring ablation and coagulation of soft tissues, including the skin Eligible subjects will undergo 3…
- Trial name
- NCT02704741
- Testing
- CO2RE
- Where
- 4 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Syneron Medical
Vagina Atrophy
Evaluation of the Safety and Efficacy of the NuEra Tight VRF for the Treatment of Vaginal and Vulvar Tissue Laxity
Up to twenty (20) healthy pre- and post-menopausal women with self-reported vaginal laxity will be enrolled in the study.
- Trial name
- NCT04511260
- Testing
- NuEra Tight VRF Handpiece
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Lumenis Be Ltd.
Vaginal Dryness, Breast Cancer
Efficacy and Safety of Vaginal Radiofrequency for Vulvovaginal Atrophy in Breast Cancer Patients
This Phase III, randomized, balanced, parallel-group, multicenter trial aims to evaluate the effect of vaginal radiofrequency on symptoms of vaginal dryness at six months.
- Conditions
- Vaginal Dryness, Breast Cancer, Vulvovaginal Atrophy
- Trial name
- RF-Vaginale (NCT06900374)
- Testing
- GynWave-360, Local hydratation
- Where
- France
- Volunteers
- 75 people
- Sponsor
- Centre Oscar Lambret
Vaginal Atrophy
DHEA Against Vaginal Atrophy - Safety Study of 12 Months
The purpose of this Phase III trial is to assess the long-term safety of intravaginal dehydroepiandrosterone (DHEA) in non-hysterectomized postmenopausal women with vaginal atrophy aged 40 to 75 years.
- Trial name
- NCT01256671
- Testing
- DHEA
- Where
- 41 sites in United States, Canada
- Volunteers
- 530 people
- Sponsor
- EndoCeutics Inc.
ALS, Amyotrophic Lateral Sclerosis
NYSCF Scientific Discovery Biobank
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells…
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset
- Trial name
- NCT06203106
- Testing
- Biological Sample Collection
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- New York Stem Cell Foundation Research Institute
Atrophic Vaginitis, Postmenopausal Atrophic Vaginitis
Estrogen and Platelet Rich Plasma in Treatment of Atrophic Vaginitis
This study is designed to compare the efficacy, acceptability, and safety of vaginal estrogen cream and platelet-rich plasma in pt. complaining of atrophic vaginitis.
- Trial name
- NCT05118685
- Testing
- Conjugated Estrogens vaginal cream 0,625mg, platelet rich plasma
- Where
- 2 sites in Egypt
- Volunteers
- 100 people
- Sponsor
- Fayoum University
Vulvovaginal Atrophy, Genital Disorder
Psychometric Validation of the Portuguese DIVAS-Q in Women With Vulvovaginal Atrophic Symptoms
To determine the reliability and validity of the Portuguese version of the DIVA questionnaire in Portuguese women. This validation will support its use both in research and in routine clinical practice in this population.
- Conditions
- Vulvovaginal Atrophy, Genital Disorder, PROMs
- Trial name
- DIVAS-Q (NCT07250490)
- Where
- Portugal
- Volunteers
- 300 people
- Sponsor
- Instituto Politécnico de Leiria
Atrophy;Vaginal
Light Emitting Diode in the Treatment of Genitourinary Syndrome of Menopause
Introduction: The genitourinary menopause syndrome (MMS) affects 50% of postmenopausal women and, due to a decrease in hormone levels, triggers functional changes in the vagina and vagina, and impairment of quality of life and…
- Trial name
- NCT04902794
- Testing
- Light Emitting Diode
- Where
- Brazil
- Volunteers
- 74 people
- Sponsor
- Patricia Lordelo
Atrophy, Vaginal Diseases
Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus
The primary objective of the study was to assess the long-term safety of 30- and 60-mg daily doses of ospemifene in the treatment of Vulvar and Vaginal Atrophy (VVA) in postmenopausal women with an intact uterus.
- Trial name
- NCT01585558
- Testing
- Ospemifene (Dose 1), Ospemifene (Dose 2)
- Volunteers
- 180 people
- Sponsor
- Shionogi
Vaginal Atrophy, Vulvar Atrophy
VG101 Phase I/II to Treat Vulvar and Vaginal Atrophy in Post-Menopausal Women
To conduct a prospective, randomized, blinded, placebo controlled, dose escalation clinical trial in 4 cohorts of 10 postmenopausal women (total N=40) aged 45 to 65 years with at least one menopausal vaginal symptom, vaginal pH >…
- Trial name
- NCT00453089
- Testing
- VG101
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bionovo
Vulvovaginal Atrophy, Dyspareunia
Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA
This is an unblinded study to be conducted at a single research center, San Diego Sexual Medicine. Subjects meeting inclusion and exclusion criteria will receive 60 mg ospemifene daily for twenty weeks.
- Trial name
- NCT02784613
- Testing
- Ospemifene
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sue Goldstein
Breast Cancer, Vaginal Dryness
Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy
It is well documented that women who have breast cancer may experience a decrease in quality of life and sexual functioning due to side effects from adjuvant endocrine therapy, typically aromatase inhibitors (AIs).
- Conditions
- Breast Cancer, Vaginal Dryness, Dyspareunia, Sexual Health Quality of Life
- Trial name
- NCT01697345
- Testing
- Testosterone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Creighton University
Primary Sjögren Syndrome
Effects of Primary Sjögren's Syndrome on Female Genitalia and Sexual Functions
A total of 68 women with pSS and 135 healthy female patients were included in the study. All women in the study and control groups were evaluated gynecologically, and genital findings during the examination and variables related…
- Trial name
- NCT04816370
- Testing
- FSFI
- Where
- Turkey (Türkiye)
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Ankara Education and Research Hospital
Atrophic Vaginitis, Menopause
Comparison of Vaginal Laser Therapy to Vaginal Estrogen Therapy
This is a multi-centered, randomized prospective single blinded clinical trial comparing CO2 fractionated vaginal laser therapy and vaginal estrogen cream therapy in the treatment of vulvovaginal atrophy/GSM.
- Trial name
- VeLVET (NCT02691936)
- Testing
- CO2 fractionated vaginal laser, Estrogens, Conjugated (USP)
- Where
- 6 sites in United States
- Volunteers
- 69 people
- Sponsor
- The Cleveland Clinic
Menopause
Estrogen and the Urogenital Microbiome in GSM
This is a study of how local estrogen treatment affects the microbiome of the vagina and bladder in postmenopausal women experiencing symptoms as part of "Genitourinary Syndrome of Menopause." The goal is to understand more about…
- Trial name
- NCT03336437
- Testing
- Estradiol vaginal ring
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Vulvovaginal Atrophy
Investigation of Efficacy and Tolerability of a Lactic Acid Containing Vaginal Suppository in Post-menopausal Women With VVA
The aim of the study is to investigate the efficacy and tolerability of a lactic acid containing vaginal suppository with respect to the application in post-menopausal women with VVA.
- Trial name
- NCT04222647
- Testing
- WO533
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel